Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen has been struggling to grow its revenue at a good clip organically. The company's pipeline and a recent acquisition should help it improve.

Is Amgen Stock a Buy Now?

Honeywell

UnitedHealth Group

While investing in Dow stocks – that is, the 30 companies making up the Dow Jones Industrial Average – might seem incredibly boring, investors shouldn't outright dismiss this avenue for potential profitability. I consider this segment to be the Mike Tyson of the equities market.

Hot Stocks: The 3 Best Opportunities for Investing in the Dow

Agilent Technologies

Apple

AbbVie

Accenture Plc

Automatic Data Processing

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Brookfield Infrastructure

Booking Hlds

Blackrock Inc

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

CME Group

I have been actively reshaping my portfolio by selling off low-conviction holdings and focusing on high-growth compounders. I have reduced my holdings from roughly 90 to roughly 70 over the past 6 months or so. I am excited about my current allocations and believe my portfolio changes will set them up for continued double-digit annual income growth.

More Big Changes To My Dividend Growth Portfolio

BHP Billiton

Kraft Heinz

Rio Tinto plc Sponsored

As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve continue, and investors find themselves at a juncture where prudence meets opportunity.

4 Oversold Large Cap Stocks Yielding High Dividends

Amgen is a solid dividend growth company with a 12-year streak of raising dividends and a healthy payout ratio. The company is well-positioned to benefit from increased medical spending and the expansion of its drug portfolio. AMGN stock has a potential upside of 14% and the dividend has a growth CAGR in the double digits for the last 10-year period.

Amgen Will Benefit From Increased Medical Spending

Novo Nordisk

Pfizer

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis.

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif. , March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Chevron

Hess

Blue Owl Capital

Southern Company

Simon Property Group

This leading company has rallied big off the 2023 lows, pays a fat 5.18% dividend, and looks ready to break out.

6 Of Goldman Sachs Top 2024 Stock Picks Also Pay Big Dividends

American Express

Philip Morris

The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.

Daily Dividend Report: GD, Amgen, American Express, Philip Morris, KAI

THOUSAND OAKS, Calif. , March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024.

AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND

Cisco Systems

Verizon

Cisco's recent results look relatively weak, but there's a noteworthy reason. There's also hope on the horizon.

Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?

Amgen Inc. (AMGN) Presents at TD Cowen 44th Annual Health Care Conference (Transcript)

In the closing of the recent trading day, Amgen (AMGN) stood at $279.35, denoting a -0.35% change from the preceding trading day.

Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to Know

BioNTech SE

Eli Lilly

Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.

It's Time! 3 Dodgy Pharma Stocks to Sell in February

Amgen is arguably one of the most impressive companies in its industry.

Amgen: A Good Dividend Growth Stock For The Watch List

Boeing

Caterpillar

Salesforce

Disney

Dow Inc

Goldman Sachs

Intel

Johnson & Johnson

Coca-Cola

McDonald's

Microsoft

NIKE

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–DowJones&Co. The highest-yield 10 stocks are March's Dogs of the Dow: GS, JNJ, KO, AMGN, CSCO, IBM, CVX, DOW, MMM, and VZ. They only averaged a 4.15% annual yield. Thirty Dow stocks represent nine of eleven sectors. DowJones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated March net-gains ranged 12.35%-25.79%, topped by BA 2/29/24.

March Dogs Of The Dow: Buy 1; Watch 4

THOUSAND OAKS, Calif. , Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.

AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Dividend growth stocks have consistently outshined most other asset classes over the past 124 years. AbbVie and Amgen are two of the brightest stars within the healthcare dividend growth stock landscape.

Better Dividend Growth Stock: AbbVie or Amgen?

Analysts are already calling for Dow 40,000. And they think just eight S&P 500 stocks will drive a bulk of the huge surge.

Analysts: 8 Stocks Will Power The Run To Dow 40,000

THOUSAND OAKS, Calif. , Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO

Axsome Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.

3 Biotech Stocks to Buy and Hold for the Next 10 Years

News for Amgen Stock (AMGN)